Goldman Sachs analyst Chris Shibutani maintains Johnson & Johnson (NYSE:JNJ) with a Neutral and lowers the price target from $160 to $155.
Goldman Sachs Maintains Neutral on Johnson & Johnson, Lowers Price Target to $155
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.